COMPANY

MacroGenics

HQ: Rockville, MD source · macrogenics.com ↗ · Mid-Atlantic

Keywords: antibody oncology cancer immunology hematology antibody-drug conjugate Colorectal Cancer Pancreatic Cancer Squamous Cell Carcinoma of Head and Neck Non Small Cell Lung Cancer Small-cell Lung Cancer Bladder Cancer Melanoma Castration Resistant Prostatic Cancer Gastric Cancer Breast Cancer Ovarian Cancer Head and Neck Cancer Type 1 Diabetes Mellitus Prostate Cancer smallpox Esophageal Cancer Endometrial Cancer Cervical Cancer Clear Cell Renal Cell Carcinoma Platinum-resistant Ovarian Cancer Acute Myeloid Leukemia Androgen-Independent Prostatic Cancer Androgen-Resistant Prostatic Cancer Hormone Refractory Prostatic Cancer Cholangiocarcinoma Colorectal Carcinoma Head and Neck Squamous Cell Carcinoma Malignant Melanoma Renal Cell Carcinoma Triple Negative Breast Cancer Human Immunodeficiency Virus Type 1 AML West Nile Virus Infection Urothelial Cancer GastroEsophageal Cancer Sarcoma Gastro-esophageal Cancer

Location: Rockville, MD · source · Oct 15, 2026

Profile checked Oct 10, 2026

42Trials (company is sponsor)26NIH grants

Timeline

2026-09 Trial start Phase 1: A Study of MGC030 in Participants With Advanced Solid Tumors source ↗
May 4, 2026 Debt Debt financing announced May 4, 2026. Source: SEC filing. source ↗
Jun 10, 2025 Debt Debt financing announced Jun 10, 2025. Source: SEC filing. source ↗
May 1, 2025 Trial start Phase 2: A Study of Lorigerlimab in Participants With Advanced Solid Tumors source ↗
Feb 13, 2025 Trial start Phase 1: A Study of MGC028 in Participants With Advanced Solid Tumors source ↗
Mar 6, 2024 Trial start Phase 1: A Study of MGC026 in Participants With Advanced Solid Tumors source ↗
Sep 28, 2023 Trial start Phase 2: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer source ↗
Jun 13, 2023 Trial start Phase 2: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors source ↗
Sep 26, 2022 Trial start Phase 1: A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy source ↗
Jul 13, 2022 Trial start Phase 1: A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies source ↗
Apr 19, 2022 Trial start Phase 1: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors source ↗
Mar 17, 2021 Trial start Phase 2: Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer source ↗
2019-10 Trial start Phase 2/Phase 3: Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck source ↗
Sep 30, 2019 Trial start 2: Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer source ↗
Dec 12, 2018 Trial start Phase 1: MGD019 DART® Protein in Unresectable/Metastatic Cancer source ↗
Nov 21, 2018 Trial start Phase 1/Phase 2: MGC018 With or Without MGA012 in Advanced Solid Tumors source ↗
Sep 25, 2018 Trial start Phase 1: MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy source ↗
Jun 4, 2018 Trial start Phase 1/Phase 2: MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer source ↗
Feb 27, 2018 Trial start Phase 1: MGD009/MGA012 Combination in Relapsed/Refractory Cancer source ↗
Aug 18, 2017 Trial start Phase 1: A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms source ↗
2016-12 Trial start Phase 1: Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors source ↗
2016-01 Trial start Phase 1/Phase 2: Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer source ↗
2015-09 Trial start Phase 1: Safety Study of MGD009 in B7-H3-expressing Tumors source ↗
Aug 24, 2015 Trial start Phase 3: Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer source ↗
2015-07 Trial start Phase 1: Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer source ↗

Showing 25 of 42 dated events.

Upcoming milestones

2026-11 (ESTIMATED) · Phase 1 · A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies · NCT05362773
2026-11 (ESTIMATED) · Phase 1 · A Study of MGC028 in Participants With Advanced Solid Tumors · NCT06723236
2027-07 (ESTIMATED) · Phase 2 · A Study of Lorigerlimab in Participants With Advanced Solid Tumors · NCT06730347
2028-05 (ESTIMATED) · Phase 1 · A Study of MGC026 in Participants With Advanced Solid Tumors · NCT06242470
2028-09 (ESTIMATED) · Phase 1 · A Study of MGC030 in Participants With Advanced Solid Tumors · NCT07822399

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Debt: amount not published. Last 2 years.

May 4, 2026 Debt financing announced May 4, 2026. Source: SEC filing. source ↗
Jun 10, 2025 Debt financing announced Jun 10, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 42

Record	Title	Phase	Status	Start	Primary completion
NCT07822399	A Study of MGC030 in Participants With Advanced Solid Tumors	Phase 1	Not yet recruiting	2026-09	2028-09 (estimated)
NCT06242470	A Study of MGC026 in Participants With Advanced Solid Tumors	Phase 1	Recruiting	Mar 6, 2024	2028-05 (estimated)
NCT05362773	A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies	Phase 1	Active, not recruiting	Jul 13, 2022	2026-11 (estimated)
NCT06730347	A Study of Lorigerlimab in Participants With Advanced Solid Tumors	Phase 2	Recruiting	May 1, 2025	2027-07 (estimated)
NCT05848011	A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer	Phase 2	Completed	Sep 28, 2023	Feb 19, 2026 (actual)
NCT06723236	A Study of MGC028 in Participants With Advanced Solid Tumors	Phase 1	Recruiting	Feb 13, 2025	2026-11 (estimated)
NCT05551117	A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors	Phase 2	Terminated	Jun 13, 2023	Jul 4, 2024 (actual)
NCT05293496	A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors	Phase 1	Completed	Apr 19, 2022	Jun 24, 2025 (actual)
NCT02475213	Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer	Phase 1	Completed	2015-07	Aug 18, 2021 (actual)
NCT03729596	MGC018 With or Without MGA012 in Advanced Solid Tumors	Phase 1/Phase 2	Terminated	Nov 21, 2018	Mar 18, 2023 (actual)
NCT04082364	Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer	2	Completed	Sep 30, 2019	Jan 15, 2024 (actual)
NCT05261191	A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy	Phase 1	Completed	Sep 26, 2022	May 29, 2024 (actual)
NCT02689284	Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer	Phase 1/Phase 2	Completed	2016-01	2021-01 (actual)
NCT02492711	Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer	Phase 3	Completed	Aug 24, 2015	Aug 11, 2021 (actual)
NCT01828021	Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer	2	Completed	2013-03	Dec 7, 2016 (actual)
NCT03761017	MGD019 DART® Protein in Unresectable/Metastatic Cancer	Phase 1	Completed	Dec 12, 2018	Aug 29, 2024 (actual)
NCT01148849	Safety Study of MGAH22 in HER2-positive Carcinomas	Phase 1	Completed	2010-07	Jun 14, 2022 (actual)
NCT02152956	Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)	Phase 1/Phase 2	Terminated	Jun 9, 2014	Jul 5, 2022 (actual)
NCT03219268	A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms	Phase 1	Completed	Aug 18, 2017	Feb 8, 2023 (actual)
NCT00920582	Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus	Phase 3	Terminated	2009-09	2012-04 (actual)
NCT04634825	Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer	Phase 2	Terminated	Mar 17, 2021	Jul 29, 2022 (actual)
NCT00385697	The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus	Phase 2/Phase 3	Completed	2006-10	2010-06 (actual)
NCT00625586	Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer	Phase 2	Terminated	Apr 15, 2008	Jan 21, 2009 (actual)
NCT00870818	Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)	Not phased (device or behavioral study)	Terminated	2009-02	2011-02 (actual)
NCT03570918	MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy	Phase 1	Completed	Sep 25, 2018	Sep 28, 2021 (actual)
NCT04678466	Flotetuzumab Expanded Access Program	Not listed	No longer available	Not listed	Not listed
NCT03406949	MGD009/MGA012 Combination in Relapsed/Refractory Cancer	Phase 1	Completed	Feb 27, 2018	Apr 27, 2022 (actual)
NCT00515385	A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults	Phase 1	Completed	2007-08	2008-12 (actual)
NCT00101972	RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma	Phase 1	Completed	2004-12	2008-05 (actual)
NCT01206504	Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure	Not listed	No longer available	Not listed	Not listed
NCT00927953	Treatment of West Nile Virus With MGAWN1	Phase 2	Terminated	2009-05	2011-02 (actual)
NCT00954915	Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis	Phase 1/Phase 2	Terminated	2009-12	2010-07 (actual)
NCT02376036	Phase 1 Study of MGD010 in Healthy Subjects	1	Completed	2015-02	2017-02 (actual)
NCT02248805	Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma	1	Completed	2014-10	Jul 2, 2018 (actual)
NCT04129320	Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck	Phase 2/Phase 3	Withdrawn	2019-10	2020-10 (estimated)
NCT01391143	Safety Study of MGA271 in Refractory Cancer	Phase 1	Completed	2011-07	Apr 18, 2019 (actual)
NCT01189422	Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes	Phase 1	Terminated	2010-08	2011-02 (actual)
NCT03531632	MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer	Phase 1/Phase 2	Completed	Jun 4, 2018	Feb 8, 2020 (actual)
NCT01918930	Tissue Procurement Substudy for Participants in Study CP-MGA271-01	Phase 1	Terminated	2013-07	2016-10 (actual)
NCT02628535	Safety Study of MGD009 in B7-H3-expressing Tumors	Phase 1	Terminated	2015-09	Nov 25, 2019 (actual)
NCT02982941	Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors	Phase 1	Completed	2016-12	May 22, 2019 (actual)
NCT02381314	Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer	Phase 1	Completed	Mar 26, 2015	Nov 9, 2017 (actual)

NIH awards 26

Annual award amounts. Total $42.4M.

2021 NIH contract (government contract; not a grant and not an investment round) 272201500032C-P00008-9999-1 FY2021: $6,287,950 awarded for that fiscal year; activity N01 (OTHER_NIH); PI NORDSTROM, JEFFREY; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. DU source ↗
2018 NIH contract (government contract; not a grant and not an investment round) 272201500032C-3-0-1 FY2018: $1,263,565 awarded for that fiscal year; activity N01 (OTHER_NIH); PI NORDSTROM, JEFFREY; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. DUAL AFFIN source ↗
2017 NIH contract (government contract; not a grant and not an investment round) 272201500032C-2-0-1 FY2017: $10,790,360 awarded for that fiscal year; activity N01 (OTHER_NIH); PI NORDSTROM, JEFFREY; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. DUAL AFFI source ↗
2015 NIH contract (government contract; not a grant and not an investment round) 272201500032C-0-0-1 FY2015: $7,449,454 awarded for that fiscal year; activity N01 (OTHER_NIH); PI NORDSTROM, JEFFREY; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. IGF::OT::I source ↗
May 6, 2013 NIH award 5R01AI089588-04 FY2013: $1,185,525 awarded for that fiscal year; activity R01 (OTHER_NIH); PI JOHNSON, L SYD; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. A Pan-Dengue Virus Immunotherapeutic for source ↗
May 31, 2012 NIH award 5R01AI089588-03 FY2012: $1,262,889 awarded for that fiscal year; activity R01 (OTHER_NIH); PI JOHNSON, L SYD; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. A Pan-Dengue Virus Immunotherapeutic for source ↗
Jul 22, 2011 NIH award 5R01AI089588-02 FY2011: $1,197,162 awarded for that fiscal year; activity R01 (OTHER_NIH); PI JOHNSON, L SYD; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. A Pan-Dengue Virus Immunotherapeutic for source ↗
Jun 17, 2010 NIH award 1R01AI089588-01 FY2010: $1,018,661 awarded for that fiscal year; activity R01 (OTHER_NIH); PI JOHNSON, L SYD; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. A Pan-Dengue Virus Immunotherapeutic for source ↗
Jun 7, 2010 NIH award 1RC3AI089207-01 FY2010: $2,999,972 awarded for that fiscal year; activity RC3 (OTHER_NIH); PI MOORE, PAUL ANDREW; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. Development of a Novel Bi-Specific A source ↗
Aug 12, 2009 NIH award 5U01AI070504-04 FY2009: $1,847,366 awarded for that fiscal year; activity U01 (OTHER_NIH); PI NORDSTROM, JEFFREY L; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. Cocktail of Neutralizing MAbs for source ↗
Jun 25, 2008 NIH award 5U01AI070504-03 FY2008: $1,975,114 awarded for that fiscal year; activity U01 (OTHER_NIH); PI NORDSTROM, JEFFREY L; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. Cocktail of Neutralizing MAbs for source ↗
Jun 25, 2007 NIH award 5U01AI070504-02 FY2007: $1,531,637 awarded for that fiscal year; activity U01 (OTHER_NIH); PI NORDSTROM, JEFFREY L; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. Cocktail of Neutralizing MAbs for source ↗
Jul 12, 2006 NIH award 1U01AI070504-01 FY2006: $867,437 awarded for that fiscal year; activity U01 (OTHER_NIH); PI NORDSTROM, JEFFREY L; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. Cocktail of Neutralizing MAbs for Sm source ↗
Sep 24, 2004 NIH award 5R44CA097632-03 FY2004: $513,256 awarded for that fiscal year; activity R44 (SBIR); PI STAVENHAGEN, JEFFREY B; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. Enhancement of the immune response by F source ↗
Jul 6, 2004 NIH award 1R43AI056745-01A1 FY2004: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI FERGUSON, STACY E.; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. Development of Novel Brucella Vaccine Can source ↗
May 24, 2004 NIH award 1R43CA103292-01A1 FY2004: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI RANKIN, CHRISTOPHER T; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. Role of anti-Fc Gamma RIIB antibody in source ↗
Mar 25, 2004 NIH award 3R44CA097632-02S1 FY2004: $128,664 awarded for that fiscal year; activity R44 (SBIR); PI STAVENHAGEN, JEFFREY B; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. Enhancement of the immune response by source ↗
Mar 10, 2004 NIH award 1R43CA105677-01 FY2004: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI TJOELKER, LARRY; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. Melanoma Proteins in Serum and Urine source ↗
Feb 25, 2004 NIH award 1R43AI052549-01A2 FY2004: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI JOHNSON, LESLIE S; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. FcRlll Blockade as a Treatment for Autoimm source ↗
Jan 30, 2004 NIH award 1R43AI058329-01 FY2004: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI JOHNSON, LESLIE S; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. Development of Soluble FcR-Ig Fusion Protein source ↗
Sep 30, 2003 NIH award 2R44CA097632-02 FY2003: $660,308 awarded for that fiscal year; activity R44 (SBIR); PI STAVENHAGEN, JEFFREY B; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. Enhancement of the immune response by F source ↗
Sep 4, 2003 NIH award 1R43AI056802-01 FY2003: $500,000 awarded for that fiscal year; activity R43 (SBIR); PI NORDSTROM, JEFFREY L; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. Vaccine discovery for Burkholderia via pr source ↗
Aug 1, 2003 NIH award 1R43CA099481-01 FY2003: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI VON HALLER, PRISKA; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. Finding membrane proteins in cutaneous T-ce source ↗
Jun 16, 2003 NIH award 1R43CA103284-01 FY2003: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI SCHUMMER, MICHEL; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. Finding plasma membrane proteins in prostate source ↗
Jun 5, 2003 NIH award 1R43CA101287-01 FY2003: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI RANKIN, CHRISTOPHER T; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. Superantigens in Epstein-Barr Virus Path source ↗
Sep 30, 2002 NIH award 1R43CA097632-01 FY2002: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI STAVENHAGEN, JEFFREY B; recipient as written: MACROGENICS, INC., ROCKVILLE, MD. Enhancement of The Immune Respose By Fc source ↗